NEW YORK (GenomeWeb News) – One day after saying that its third-quarter revenues would fail to meet expectations, Cepheid said on Thursday that it is acquiring a plastics company and bringing at least some of its molding operations in-house.

Company officials also said that the firm has signed the second of three agreements aimed at increasing adoption of its Xpert MTB/RIF test in resource-poor areas of the world with multi-drug-resistant tuberculosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.